Novavax (NVAX) Gains from Investment Securities (2016 - 2025)
Historic Gains from Investment Securities for Novavax (NVAX) over the last 16 years, with Q3 2025 value amounting to $3.9 million.
- Novavax's Gains from Investment Securities rose 25286.62% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.8 million, marking a year-over-year increase of 33936.12%. This contributed to the annual value of $21.8 million for FY2024, which is 2024.5% down from last year.
- Per Novavax's latest filing, its Gains from Investment Securities stood at $3.9 million for Q3 2025, which was up 25286.62% from $21.5 million recorded in Q2 2025.
- In the past 5 years, Novavax's Gains from Investment Securities registered a high of $64.0 million during Q4 2021, and its lowest value of -$16.6 million during Q1 2025.
- Moreover, its 5-year median value for Gains from Investment Securities was $10.3 million (2021), whereas its average is $14.7 million.
- Per our database at Business Quant, Novavax's Gains from Investment Securities soared by 346264.04% in 2021 and then crashed by 48896.25% in 2024.
- Novavax's Gains from Investment Securities (Quarter) stood at $64.0 million in 2021, then dropped by 25.52% to $47.7 million in 2022, then plummeted by 95.14% to $2.3 million in 2023, then surged by 677.19% to $18.0 million in 2024, then tumbled by 78.48% to $3.9 million in 2025.
- Its last three reported values are $3.9 million in Q3 2025, $21.5 million for Q2 2025, and -$16.6 million during Q1 2025.